Smallpox clinical trials
The registry lists 73 studies for Smallpox across more than 10 countries. 5 are recruiting or about to start. Per ClinicalTrials.gov, last updated 2026-09-14.
Status
- Completed
- 60
- Active, not recruiting
- 3
- Recruiting
- 2
- Withdrawn
- 2
- Terminated
- 2
- Not yet recruiting
- 1
Phase
- Phase 2
- 32
- Phase 1
- 27
- Phase 3
- 11
- Phase 4
- 3
Where
- United States
- 48
- Germany
- 5
- Korea, Republic of
- 4
- Democratic Republic of the Congo
- 3
- Russian Federation
- 3
- Puerto Rico
- 2
Who runs them
National Institute of Allergy and Infectious Diseases (NIAID) (18) · Bavarian Nordic (14) · SIGA Technologies (8) · Emergent BioSolutions (8) · Sanofi Pasteur, a Sanofi Company (5) · Seoul National University Hospital (4) · Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector" (3) · Sanofi (2)
Studies
Recruiting first, then most recently updated. Showing 50 of 73 — search for more.
- A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine Candidate in AfricaRecruitingNCT07379580Phase 22 countries
- Tecovirimat (ST-246) Treatment for Orthopox Virus ExposureAvailableNCT02080767
- VA-005 Clinical Outcomes of VIGIV Treatment of Smallpox Vaccination Complications or Vaccinia InfectionEnrolling by invitationNCT01374984
- Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BSY001 After Single/Multiple Doses.RecruitingNCT07377175Phase 11 country
- Assessment of Myocarditis After Replication-Deficient Smallpox ImmunizationNot yet recruitingNCT05513313
- Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOSActive, not recruitingNCT04957485Phase 21 country
- Safety, Tolerability and PK of TPOXX in Adults Weighing More Than 120 KGCompletedNCT04392739Phase 41 country
- Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate BindersCompletedNCT04485039Phase 41 country
- Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 DaysCompletedNCT04971109Phase 31 country
- A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound TecovirimatCompletedNCT02474589Phase 31 country
- Safety, Tolerability, Pharmacokinetics (PK) of the Anti-Orthopox Drug, ST-246CompletedNCT00907803Phase 21 country
- A Phase 4, Observational Field Study to Evaluate TPOXX in Patients With SmallpoxWithdrawnNCT039721111 country
- Phase 3 Infant Safety & Immunogenicity Trial of MVA-BN® in DRCActive, not recruitingNCT06844487Phase 31 country
- Phase 3 Maternal Safety & Immunogenicity Trial of MVA-BN® in DRCActive, not recruitingNCT06844500Phase 31 country
- MVA Post-Event: Administration Timing and Boost StudyCompletedNCT00437021Phase 1/21 country
- A Study to Investigate The Safety, Tolerability, And Immune Response of a Range of Doses of mRNA-1769 Compared With Placebo in Healthy Participants From ≥18 Years of Age to <50 Years of AgeCompletedNCT05995275Phase 1/21 country
- High Dose IMVAMUNE® in Vaccinia-Naive IndividualsCompletedNCT00879762Phase 21 country
- Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy AdultsCompletedNCT05935917Phase 11 country
- VA-006 Vaccinia Vaccine (ACAM2000) for the Production of VIGIVCompletedNCT01158157Phase 31 country
- Post-licensure Department of Defense (DOD) Screening Accuracy Study in Military PersonnelCompletedNCT015409291 country
- Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated AdultsCompletedNCT00053482Phase 21 country
- Effect of Dose, Safety, Tolerability of a New Smallpox Vaccine in Adults Without Previous Smallpox VaccinationCompletedNCT00053495Phase 21 country
- Safety Surveillance Study of ACAM2000® Vaccinia VaccineCompletedNCT009277191 country
- VA-008 ACAM2000® Vaccination of Plasma Donors for the Production of VIGIVCompletedNCT02443623Phase 41 country
- Study of the Safety, Tolerability, Pharmacokinetics of NIOCH-14 in Volunteers Aged 18-50 YearsCompletedNCT05976100Phase 11 country
- Study on Immunogenicity, Reactogenicity and Safety of the VACΔ6 Vaccine in Volunteers Aged 18-60 YearsCompletedNCT05846243Phase 2/31 country
- Safety and Tolerability Study of the VAC∆6 Vaccine in Volunteers Aged 18-40 YearsCompletedNCT05762523Phase 11 country
- Freeze-Dried MVA-BN® Lot Consistency Smallpox TrialCompletedNCT03699124Phase 31 country
- Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid IMVAMUNE® (1x10^8 TCID50) Administered Subcutaneously and a Lower Dose Liquid IMVAMUNE® (2x10^7 TCID50) Administered IntradermallyCompletedNCT00914732Phase 21 country
- A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy SubjectsCompletedNCT01668537Phase 21 country
- Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV InfectionCompletedNCT02038881Phase 22 countries
- Immune Responses to Smallpox VaccinationCompletedNCT003259751 country
- An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 VaccineesCompletedNCT00686582Phase 21 country
- A Randomized, Double-blind, Placebo-controlled Study on Immunogenicity and Safety of MVA-BN (IMVAMUNE™) Smallpox Vaccine in Healthy SubjectsCompletedNCT00316524Phase 21 country
- A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced SubjectsCompletedNCT00857493Phase 21 country
- Dose-finding Study to Evaluate Immunogenicity of Three Different Dose Levels of the IMVAMUNE (MVA-BN) Smallpox Vaccine.CompletedNCT00189956Phase 21 country
- Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in Patients With Atopic DisordersCompletedNCT00189917Phase 11 country
- A Phase II Study on Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in Subjects With Atopic DermatitisCompletedNCT00316602Phase 22 countries
- A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve SubjectsCompletedNCT01144637Phase 31 country
- Safety and Immunogenicity of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in HIV Infected PatientsCompletedNCT00316589Phase 22 countries
- Poly-ICLC to Prevent Respiratory Viral Infections A Safety StudyCompletedNCT00646152Phase 11 country
- Phase II Trial to Assess Safety and Immunogenicity of IMVAMUNE®CompletedNCT01827371Phase 21 country
- Phase I Trial of an Investigational Small Pox MedicationCompletedNCT00728689Phase 11 country
- VHA Clinicians and Bioterror Events: Interactive Web-based LearningCompletedNCT00123396Not applicable1 country
- ACAM 3000 MVA at Harvard Medical SchoolCompletedNCT00133575Phase 1/21 country
- Combination Study With MVA BN and DryvaxCompletedNCT00082446Phase 11 country
- Expanded Dryvax Dilution Study in Previously Vaccinated AdultsCompletedNCT00050505Phase 21 country
- Dose Safety, Tolerability, and Immunogenicity of a New Smallpox Vaccine in Adults Without Previous Smallpox VaccinationTerminatedNCT00053508Phase 21 country
- Safety Study of MVA Smallpox Vaccine in HIV-positive Subjects Who Are Vaccinia NaiveTerminatedNCT00282581Phase 11 country
- Phase 2 Study of Safety, Tolerability, and Immunogenicity of Three Dose Levels of ACAM3000 Smallpox VaccineCompletedNCT00466245Phase 2